ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Felodipine: Pediatric drug information

Felodipine: Pediatric drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Felodipine: Drug information" and "Felodipine: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: Canada
  • APO-Felodipine;
  • Plendil;
  • SANDOZ Felodipine
Therapeutic Category
  • Antihypertensive Agent;
  • Calcium Channel Blocker;
  • Calcium Channel Blocker, Dihydropyridine
Dosing: Pediatric
Hypertension

Hypertension: Limited data available: Children ≥6 years and Adolescents: Oral: Initial: 2.5 mg once daily; may increase as needed at 2-week intervals to a maximum daily dose: 10 mg/day (Ref)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no pediatric specific recommendations available; based on experience in adult patients, no dosage adjustments necessary; use with caution.

Dosing: Hepatic Impairment: Pediatric

There are no pediatric specific recommendations available; based on experience in adult patients, initial dosage adjustments suggested; monitor blood pressure closely during titration.

Dosing: Adult

(For additional information see "Felodipine: Drug information")

Angina, chronic stable

Angina, chronic stable (alternative agent) (off-label use): Note: A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a calcium channel blocker (typically a dihydropyridine [eg, felodipine]) may be added; felodipine may be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (Ref).

Oral: Initial: 5 to 10 mg once daily; if initiated at 5 mg, increase dose to 10 mg once daily as tolerated after 2 to 4 weeks (Ref).

Hypertension

Hypertension: Note: For initial treatment in patients with blood pressure ≥20/10 mm Hg above goal, may be used in combination with another appropriate agent (eg, ACE inhibitor, ARB, or thiazide diuretic). For patients <20/10 mm Hg above goal, some experts recommend an initial trial of monotherapy; however, over time, many patients will require combination therapy (Ref).

Oral: Initial: 2.5 to 5 mg once daily; titrate every 1 to 2 weeks as needed based on patient response; usual dose range: 2.5 to 10 mg once daily (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

No dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

Initial: 2.5 mg once daily; monitor blood pressure closely during titration.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Peripheral edema (2% to 17%)

Central nervous system: Headache (11% to 15%)

1% to 10%: Cardiovascular: Flushing (4% to 7%), tachycardia (≤3%)

<1%, postmarketing, and/or case reports: Abdominal pain, acid regurgitation, anemia, angina pectoris, angioedema, anxiety disorder, arm pain, arthralgia, back pain, bronchitis, bruise, cardiac arrhythmia, cardiac failure, cerebrovascular accident, chest pain, constipation, decreased libido, depression, diarrhea, dizziness, drowsiness, dyspnea, dysuria, epistaxis, erythema, extrasystoles, facial edema, flatulence, flu-like symptoms, flushing, foot pain, gingival hyperplasia, gynecomastia, hip pain, hypersensitivity angiitis, hypotension, impotence, influenza, insomnia, irritability, knee pain, leg pain, muscle cramps, myalgia, myocardial infarction, nausea, nervousness, palpitations, paresthesia, pharyngitis, polyuria, psoriasis (Song 2021), respiratory tract infection, sinusitis, syncope, urinary frequency, urinary urgency, urticaria, visual disturbance, vomiting, xerostomia

Contraindications

Hypersensitivity to felodipine or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to other dihydropyridines; women of childbearing potential, in pregnancy, and during lactation.

Warnings/Precautions

Concerns related to adverse effects:

• Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers; reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease especially in the absence of concurrent beta-blockade.

• Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.

• Peripheral edema: The most common side effect is peripheral edema (dose dependent); occurs within 2 to 3 weeks of starting therapy.

Disease-related concerns:

• Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.

• Heart failure: The ACC/AHA heart failure guidelines recommend to avoid use in patients with heart failure (HF) due to lack of benefit and/or worse outcomes with calcium channel blockers in general (AHA/ACC/HFSA [Heidenreich 2022]).

• Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.

• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.

Special populations:

• Older adult: Initiate at a lower dose in the elderly.

Dosage forms specific issues:

• Lactose: May contain lactose; if necessary, consider alternative agents in patients intolerant of lactose.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet Extended Release 24 Hour, Oral:

Generic: 2.5 mg, 5 mg, 10 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablet, 24-hour (Felodipine ER Oral)

2.5 mg (per each): $1.22 - $1.58

5 mg (per each): $1.08 - $1.58

10 mg (per each): $2.18 - $3.72

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet Extended Release 24 Hour, Oral:

Plendil: 2.5 mg, 5 mg, 10 mg

Generic: 2.5 mg, 5 mg, 10 mg

Administration: Pediatric

Oral: Swallow tablet whole; do not divide, crush, or chew. May be administered without food or with a small meal that is low in fat and carbohydrates.

Administration: Adult

Oral: Swallow tablet whole; tablet should not be divided, crushed, or chewed. May be administered without food or with a small meal that is low in fat and carbohydrates.

Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation exists. Consider switching to a different dihydropyridine calcium channel blocker that is available in IR formulation.

Storage/Stability

Store below 30°C (86°F); protect from light.

Use

Treatment of hypertension alone or in combination with other antihypertensives (FDA approved in adults)

Medication Safety Issues
Sound-alike/look-alike issues:

Plendil may be confused with Isordil, pindolol, Pletal, PriLOSEC, Prinivil

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2D6 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider therapy modification

Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk X: Avoid combination

Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers. Risk C: Monitor therapy

Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. Risk C: Monitor therapy

CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Risk C: Monitor therapy

CYP3A4 Inducers (Moderate): May decrease the serum concentration of Felodipine. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Felodipine. Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Felodipine. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Felodipine. Management: Consider using lower felodipine doses when combined with strong CYP3A4 inhibitors. Monitor patients for increased felodipine effects and toxicities (eg, hypotension, edema) when combined. Risk D: Consider therapy modification

Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers. Risk X: Avoid combination

Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers. Risk C: Monitor therapy

Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider therapy modification

Grapefruit Juice: May increase the serum concentration of Felodipine. Risk C: Monitor therapy

Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Iloperidone: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Indoramin: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers. Risk C: Monitor therapy

Isocarboxazid: May enhance the antihypertensive effect of Antihypertensive Agents. Risk X: Avoid combination

Itraconazole: May increase the serum concentration of Felodipine. Risk X: Avoid combination

Ketoconazole (Systemic): May increase the serum concentration of Felodipine. Risk X: Avoid combination

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. Risk C: Monitor therapy

Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased. Risk C: Monitor therapy

Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine). Risk C: Monitor therapy

Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy

Talazoparib: Felodipine may increase the serum concentration of Talazoparib. Risk C: Monitor therapy

Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. Risk C: Monitor therapy

Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine. Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication. Risk D: Consider therapy modification

Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. Risk C: Monitor therapy

Food Interactions

Food: Compared to a fasted state, felodipine peak plasma concentrations are increased up to twofold when taken after a meal high in fat or carbohydrates. Grapefruit juice similarly increases felodipine Cmax by twofold. Increased therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur. Management: May be taken with a small meal that is low in fat and carbohydrates. Monitor hemodynamic response closely in patients consuming grapefruit juice concurrently; felodipine dosage adjustment and/or modification of grapefruit juice ingestion may be needed.

Dietary Considerations

May be taken with a small meal that is low in fat and carbohydrates.

Reproductive Considerations

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Felodipine is generally not considered a preferred agent for use in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019); however, use of felodipine may be considered (ESC [Cífková 2020]).

Pregnancy Considerations

Adverse events were observed in animal reproduction studies.

Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).

Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than felodipine may be preferred (ACOG 2019; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]); however, use of felodipine may be considered (ESC [Cífková 2020]).

Monitoring Parameters

Blood pressure, liver enzymes

Mechanism of Action

Inhibits calcium ions from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Antihypertensive: 2 to 5 hours

Duration of antihypertensive effect: 24 hours

Absorption: 100%; Absolute: 20% due to first-pass effect

Protein binding: >99%

Metabolism: Hepatic; CYP3A4 substrate (major); extensive first-pass effect

Half-life elimination: Immediate release: 11 to 16 hours

Time to peak: 2.5 to 5 hours

Excretion: Urine (70% as metabolites); feces 10%

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Felodipine clearance is reduced about 60% in patients with hepatic impairment.

Older adult: Plasma concentrations of felodipine increase with advancing age. Clearance of felodipine in elderly hypertensive patients was 45% of that observed in young volunteers. Steady-state mean area under curve in young patients was 39% of that observed in elderly patients.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Plendil;
  • (AR) Argentina: Munobal | Plendil;
  • (AT) Austria: Felodipin arcana | Felodipin hexal pharma | Felodipin ratiopharm | Felodistad | Munobal | Plendil;
  • (AU) Australia: Agon | Felodil | Felodur | Fendex | Plendil;
  • (BE) Belgium: Felodipine bexal | Felodipine eg | Felodipine eurogenerics | Felodipine merck-generics | Felodipine ratiopharm | Felodipine Sandoz | Plendil | Renedil;
  • (BG) Bulgaria: Auronal | Felicipin | Felodipine ratiopharm | Felohexal | Plendil | Presid;
  • (CH) Switzerland: Felodipin 1 A Pharma | Felodipin Helvepharm | Felodipin Mepha | Felodipin retard zentiva | Plendil Plain;
  • (CL) Chile: Splendil;
  • (CN) China: Bo fei ke | Etersim | Ke li ping | Li nuo | Lian huan er ding | Plendil;
  • (CZ) Czech Republic: Auronal | Felodipin | Felodipin al | Plendil | Presid;
  • (DE) Germany: Felo biochemie | Felo-puren | Felobeta | Felocor | Felodipin | Felodipin 1 A Pharma | Felodipin Actavis | Felodipin al | Felodipin dura | Felodipin Heumann | Felodipin ratiopharm | Felodipin sandoz | Felodipin stada | Felodipin von CT | Felogamma | Modip | Munobal | Plendil;
  • (DK) Denmark: Felodipin 1a farma;
  • (DO) Dominican Republic: Feldipina | Plendil;
  • (EC) Ecuador: Plendil;
  • (EE) Estonia: Felodipin | Felodipin Alpharma | Felodipin hexal | Plendil | Presid;
  • (EG) Egypt: Felocor | Felodipin stada | Healthplend | Plendil | Plentopine;
  • (ES) Spain: Fensel | Perfudal | Plendil;
  • (FI) Finland: Felodipin Alpharma | Felodipin hexal | Felodipin ratiopharm | Felodipin sandoz | Hydac | Plendil | Sekal;
  • (FR) France: Felodipine Sandoz;
  • (GB) United Kingdom: Cabren | Cardioplen xl | Delofine xl | Felendil xl | Felodipine arrow | Felodipine cox | Felodipine focus | Felodipine kent | Felodipine Sandoz | Felogen xl | Felotens xl | Folpik | Keloc | Neofel | Neofel xl | Parmid XL | Pinefeld xl | Plendil | Plendil old | Vascalpha;
  • (GR) Greece: Plendil;
  • (HK) Hong Kong: Apt Felodipine | Fedisyn | Felogard | Felostad | Plendil;
  • (HU) Hungary: Auronal | Felodipin ratiopharm | Felodipin winthrop | Plendil | Presid;
  • (ID) Indonesia: Nirmadil | Plendil;
  • (IE) Ireland: Plendil;
  • (IL) Israel: Penedil;
  • (IN) India: Felogard | Plendil | Renedil;
  • (IS) Iceland: Feldil;
  • (IT) Italy: Feloday | Felodipina Mylan | Felodipina provissoria | Felodipina Sandoz | Felodipina Winthrop | Plendil | Prevex;
  • (JO) Jordan: Plendil;
  • (JP) Japan: Catrazil | Munobal | Splendil;
  • (KE) Kenya: Enfelo | Plendil;
  • (KR) Korea, Republic of: Adipin | Aprogen felodipine | Binex felodipine | Decreapin | Decreapin sr | Dilopin | Feldipin | Fellon | Felobal | Feloden | Felodic | Felodin | Felodion | Felodip | Felodpine sik | Felopine | Feloten | Felotin | Fenodipine | Haifel | Halopin | Hidipin | Hidropin sr | Hydipin | Hydropine | Keydipin | L dipine er | L-dipine | Lodil | Lodipin | Lowperin | Munobal | Munodipine | Samik felodipine | Selepin | Splendil er | Stapin | Vaspine er | Zirodipine;
  • (KW) Kuwait: Plendil;
  • (LB) Lebanon: Plendil;
  • (LT) Lithuania: Felodipin Actavis | Felodipinhexal | Plendil | Presid;
  • (LU) Luxembourg: Felodipin | Felodipine eg | Plendil | Renedil;
  • (LV) Latvia: Felodipin | Felodipin hexal | Plendil | Presid;
  • (MX) Mexico: Eutens | Fedin | Felodipino | Felodipino raam | Feymutur | Glitazor | Hofodilan | Ivenkens | Munobal | Plendil | Tecnoplex | Xysvol;
  • (MY) Malaysia: Felocor | Plendil;
  • (NG) Nigeria: Plendil;
  • (NL) Netherlands: Felodipine Actavis | Plendil | Preslow;
  • (NO) Norway: Felodipin | Felodipin hexal | Felodipin ratiopharm | Plendil;
  • (NZ) New Zealand: Agon | Felo | Plendil er;
  • (PE) Peru: Plendil;
  • (PH) Philippines: Dilahex | Dilofen | Feldona 5 er | Felim | Felocard | Felodin | Felodipin Natrapharm | Feloence 5 er | Felojen | Felop | Felostal | Felostar | Lodistad er | Lodistad mr | Lupress | Plendil er | Ropine er | Versant xr;
  • (PK) Pakistan: Plendil;
  • (PL) Poland: Plendil;
  • (PR) Puerto Rico: Felodipine extended release | Plendil;
  • (PT) Portugal: Felodipina;
  • (QA) Qatar: Flindip | Plendil;
  • (RO) Romania: Felodipin al | Felodipin sandoz | Felohexal;
  • (RU) Russian Federation: Felodip | Felodipin sz | Plendyl;
  • (SA) Saudi Arabia: Plendil;
  • (SE) Sweden: Felodipin Actavis | Felodipin bijon | Felodipin gea | Felodipin hexal | Felodipin mylan | Felodipin omet pharma | Felodipin ratiopharm | Felodipin stada | Plendil;
  • (SG) Singapore: Felodipin stada | Plendil;
  • (SK) Slovakia: Felodipin | Plendil | Presid;
  • (TH) Thailand: Enfelo | Felim | Felodipin stada | Felodipine Sandoz | Felohexal | Feloten | Munobal | Plendil;
  • (TR) Turkey: Plendil;
  • (TW) Taiwan: Fedil | Fedisyn | Felo | Felop | Felopine | Felpin | Plendil | Polo | Stapin | Winlopine | Yalop;
  • (UA) Ukraine: Felodip | Felohexal;
  • (UG) Uganda: Plendil;
  • (VE) Venezuela, Bolivarian Republic of: Munobal | Plendil;
  • (VN) Viet Nam: Mibeplen;
  • (ZA) South Africa: Felodipine hexal | Plendil
  1. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. [PubMed 30575676]
  2. Aronow WS, Fleg JL, Pepine CJ, et al, ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434-2506. [PubMed 21518977]
  3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289(19):2560-2571.
  4. Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082 [PubMed 31841131]
  5. Cohn JN, Ziesche S, Smith R, et al. Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96(3):856-863. [PubMed 9264493]
  6. Dunselman P, Liem AH, Verdel G, Kragten H, Bosma A, Bernink P. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN). Eur Heart J. 1997;18(11):1755-1764. [PubMed 9402450]
  7. Emanuelsson H, Egstrup K, Nikus K, et al. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. Am Heart J. 1999;137(5):854-862. [PubMed 10220634]
  8. Felodipine [prescribing information]. Las Vegas, NV: Yiling Pharmaceutical Inc; July 2018.
  9. Felodipine extended-release tablets (USP) [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; March 2019.
  10. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3). [PubMed 28827377]
  11. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
  12. Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. Hypertension. [PubMed 24243703]
  13. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
  14. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. [PubMed 24352797]
  15. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 [PubMed 33637192]
  16. Lombardi T, Fiore-Donno G, Belser U, et al. Felodipine-Induced Gingival Hyperplasia: A Clinical and Histologic Study. J Oral Pathol Med. 1991;20(2):89-92. [PubMed 2016700]
  17. Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
  18. Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 7, 2023.
  19. Moncica I, Oh PI, ul Qamar I, et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child. 1995;73(2):154-156. [PubMed 7574861]
  20. National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf.
  21. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114(2)(suppl):555-576. [PubMed 15286277]
  22. NICE guideline hypertension in pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
  23. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440-2492. doi: 10.1161/CIR.0000000000000029. [PubMed 24589852]
  24. Plendil (felodipine) [prescribing information]. Wilmington, DE: AstraZeneca LP; October 2012.
  25. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. [PubMed 30165544]
  26. Rønnevik PK, Silke B, Ostergaard O. Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. Eur Heart J. 1995;16(11):1535-1541. [PubMed 8881845]
  27. Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. Published online October 5, 2021. doi:10.1111/bcp.15060 [PubMed 34611920]
  28. Steele RM, Schuna AA, Schreiber RT. Calcium Antagonist-Induced Gingival Hyperplasia. Ann Intern Med. 1994;120(8):663-664. [PubMed 8135450]
  29. Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18(6):548-553. [PubMed 12700955]
  30. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168 [PubMed 37471501]
  31. Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26. [PubMed 24341872]
  32. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065 [PubMed 29133356]
  33. Young PC, Turiansky GW, Sau P, et al. Felodipine-Induced Gingival Hyperplasia. Cutis. 1998;62(1):41-43. [PubMed 9675532]
Topic 86263 Version 329.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟